108257-41-6

Basic information

• Product Name: 4-CYANOIMIDAZOLE
• Synonyms: 4-Cyanoimidazole;4-Methyl-5-cyanoimidazole;5-Methyl-1H-imidazole-4-carbonitrile;1H-IMidazole-4-carbonitrile, 5-Methyl-;5-Methylimidazole-4-carbonitrile
• CAS NO: 108257-41-6
• Molecular Formula: C4H3N3
• Molecular Weight: 93.09
• Mol File: 108257-41-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 381℃
• Flash Point: 129℃
• Appearance: /
• Density: 1.21
• Storage Temp.: 2-8°C
• PKA: 9.60±0.10(Predicted)
• CAS DataBase Reference: 4-CYANOIMIDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CYANOIMIDAZOLE(108257-41-6)
• EPA Substance Registry System: 4-CYANOIMIDAZOLE(108257-41-6)

Safety Data

• Hazardous Substances Data: 108257-41-6(Hazardous Substances Data)

Usage

Preparation

A mixture of ethyl 4-imidazolecarboxylate (33 g) and ammonium hydroxide (250 mL) was heated to 100 C° in a sealed glass vessel for 1–7 days. The mixture was then cooled and the solid 4-imidazolecarboxamide 1443 was recovered by filtration in near quantitative yield and air dried. Dehydration was carried out by heating a solution of 4-imidazolecarboxamide 1443 (5 g) in PhPOCl2 (25 mL) at 80 C° for 12 h. The cooled reaction mixture was then poured over ice (200 mL) and adjusted to pH 11 with 50% aqueous sodium hydroxide. The 4-cyanoimidazole 1444 was isolated by extraction with ethyl acetate and concentration of the extracts in vacuo.

Upstream product

• 1379401-56-5 C₇H₉N₃O₂ 
• 77421-51-3 4⁽⁵⁾-methylimidazole-5⁽⁴⁾-carboxamide 
• 68282-53-1 5-methyl-4-formylimidazole 

Downstream Products

• 85665-04-9 5-methyl-1-β-D-ribofuranosylimidazole-4-carboxamide 

Relevant articles and documents

Synthesis of ribonucleosides of 4(5)-cyano-5(4)-methylimidazole and related 4-substituted-5-methylimidazole ribosides

-

INHIBITORS OF C-FMS KINASE

The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.